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A  mass  with  a  long  axis  of  approximately  6  cm  in  length  was  found  in  the  head  of  the
pancreas  in  a  59-year-old  man  during  a  chest  and  abdominal  CT  scan  (Fig.  1a)  carried
out  to  investigate  persistent  epigastric  pain,  which  had  been  present  for  several  weeks
and  was  not  associated  with  an  acute  phase  reaction  or  infection.  The  lesion  had  clearly
deﬁned  outlines  although  its  contents  were  heterogeneous,  alternating  between  cystic
areas  and  more  dense  areas,  which  enhanced  with  contrast  medium.  Despite  its  large
size,  it  was  not  causing  dilatation  of  the  common  bile  duct  or  a  hydrocholecyst  although
it  was  responsible  for  the  dilatation  of  the  main  pancreatic  duct  to  approximately  1  cm  in
diameter.  Because  the  mass  had  clearly  deﬁned  outlines,  and  the  fact  that  the  patient’s
tumor  markers  were  not  raised  and  his  general  health  had  not  declined,  a  neuroendocrine
tumor  was  considered  and  a  positron  emission  tomography  CT  scan  (PET  scan)  (Fig.  1b)
and  octreoscan  scintigram  were  performed.  The  scintigram  was  negative  although  the
PET-CT  showed  moderate  hyperintensity  in  the  lesion  (max  SUV  4.5).  Two  ﬁne  needle
aspiration  attempts  were  made  under  endoscopic  ultrasound  guidance  although  both  were
non-contributory.  The  patient  was  then  referred  to  our  centre  for  percutaneous  biopsy
under  CT  guidance  (Fig.  1c).  The  samples  contained  an  epithelial  proliferation  with  a
microcystic  architecture  suggestive  of  a  serous  cystadenoma.  The  microcystic  nature  of
the  mass  was  conﬁrmed  on  pancreatic  MRI  (Fig.  2)  in  which  the  septal  signal  intensities  were
enhanced  with  gadolinium  (Dotarem®, Guerbet,  France;  0.1  mmol/kg)  producing  a  tissue-
like  appearance  on  CT.  Despite  the  absence  of  visible  tissue  budding,  multidisciplinary
decision  recommended  surgical  excision  because  of  the  patient’s  clinical  signs,  which  were
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autlines in the head of the pancreas causing dilatation of the main
ein (head of white arrow). On PET-CT the whole lesion shows mod
ailures of endoscopic biopsy, a percutaneous biopsy was performed
robably  due  to  compression  of  the  main  pancreatic  duct
y  the  cystadenoma.  A  cephalic  duodeno-pancreatectomy
as  performed  together  with  partial  resection  of  the  portal
enous  trunk  because  of  adhesions  to  the  lesion.
Macroscopic  examination  of  the  resection  specimen
Fig.  3)  showed  a  clearly  delineated  6  cm  microcystic  tumor
ith  central  scarring,  no  mucus  and  no  communication
ith  the  Wirsung  duct  although  it  was  adhering  to  the
eighbouring  resected  vein  wall.  Microscopic  examination
onﬁrmed  the  diagnosis  of  microcystic  serous  cystadenoma,
hich  contained  no  atypical  cytonuclear  changes,  or  mitotic
ctivity  and  no  metastatic  lymph  node  involvement  (56
ymph  nodes  were  analyzed).  There  was  no  tumor  present
n  the  adjacent  resected  segment  of  portal  vein.
iscussion
erous  cystadenomas  make  up  approximately  20%  of  cystic
ancreatic  lesions  [1].  Seventy-ﬁve  percent  of  these  tumors
re  found  in  women,  average  age  61.5  years  old  [2].  In  70%  of
ases,  serous  cystadenomas  present  as  a  multicystic  tumor
ade  up  of  microcysts  deﬁned  as  having  a  diameter  of  2  cm
r  less.  The  cysts  are  frequently  separated  by  ﬁbrous  septa,




Mcreatic duct (white arrow) and sheathing the superior mesenteric
 hyperintensity (max SUV 4.5), which is heterogeneous (b). After 2
er CT guidance (c).
ccasionally  calciﬁed,  scarring  [3].  The  septa  are  contrast-
nhanced  and  clearly  visible  on  MRI.  Contrast  enhancement
s  more  variable  on  CT  [4].  More  occasionally,  the  lesion  may
ake  on  a  ‘‘honeycomb’’  appearance  (20%)  or  be  oligocystic
10%),  containing  only  a  few  cysts  over  2  cm  in  diameter.
MRI  is  still  the  best  investigation  to  characterize  a  cys-
ic  pancreatic  lesion,  primarily  because  of  its  excellent
ontrast  resolution.  The  standard  protocol  to  investigate
hese  lesions  involves  T2weighted  BLADE  (TR  =  3769  ms,
E  =  155  ms)  or  HASTE  (TR  =  1000  ms,  TE  =  84  ms)  sequences
ith  fat  suppression,  T1  phase  and  out  of  phase  sequences
TR  =  140  ms,  TE  =  2.4  ms)  and  T1  VIBE  3D  (TR  =  3.3  ms,
E  =  1.4  ms)  with  fat  saturation  in  the  arterial  (20—25  s),  por-
al  (60—65  s)  and  late  phases  (3—5  min).  Magnetic  resonance
holangiopancreatography  sequences  are  performed  either
n  2D  breath-hold  RARE  sequence  (TR  =  4500  ms,  TE  =  800  ms)
n  the  oblique  axial  coronal  plane  with  section  thicknesses
f  between  20  and  40  mm,  or  in  3D-TSE-restore  (TR  =  3748,
 ms,  TE  =  687  ms)  with  multiplanar  reconstructions  [5].  In
ur  case,  MRI  showed  the  typical  microcystic  appearances  of
 pancreatic  serous  cystadenoma.  This  could  have  enabled
s  to  avoid  taking  biopsy  samples  although  because  of  the
typical  CT  features  (dilatation  of  the  pancreatic  duct  and
seudo-solid  appearance),  as  well  as  difﬁculties  accessing
RI  in  time  and  the  fact  that  the  patient  was  referred  from
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Figure 2. Pancreatic MRI (a: axial T2 weighted BLADE [RT = 3769 ms,  ET = 155 ms]; b: coronal T2 weighted HASTE [RT = 1000 ms, ET = 84 ms];
c: axial T2 weighted HASTE with fat saturation [RT = 1000 ms, ET = 84 ms]; and d: axial T1 weighted VIBE [RT = 3.3 ms, ET = 1.4 ms] sequences
after gadolinium in the portal phase) showing a lesion with a microcystic architecture developing in the head of the pancreas and its
ior mesenteric vein (head of white arrow). A ﬁbrous scar is seen in the
hted sequences and is enhanced after gadolinium injection.consequences on the main pancreatic duct (white arrow) and super
centre of the lesion (black arrow), which is hypointense on T2 weig
outside  for  a  percutaneous  biopsy  after  failure  of  endoscopy,
we  felt  unable  to  question  the  initial  diagnostic  assumptions.
Several  atypical  morphological  features  may  be  seen  in
serous  cystadenomas,  raising  the  question  of  the  differential
diagnoses.  These  include  a  hemorrhagic  component  within
the  lesion,  excessive  tumor  growth,  disseminated  cystade-
noma,  appearances  of  a  uniloculated  cyst  or  a  solid  variant
[6].  The  presence  of  septa  within  the  lesion  and  relatively
non-speciﬁc  morphological  features  may  be  seen  in  the  cys-
tadenomas  and  even  in  mucinous  cystadenocarcinomas  [7].
Signiﬁcant  dilatation  of  the  Wirsung  duct  is  only  rarely  seen
and  generally  occurs  with  bulky  tumors.
We  decided  to  offer  or  propose  surgery  to  our  patient
because  of  the  atypical  radiological  features  and  the  fact
that  it  was  symptomatic.  The  histological  features  were
in  fact  typical  and  excluded  the  other  possible  diag-
noses,  which  were  principally  intraductal  papillary  mucinous
neoplasm  (IPMN)  (whether  or  not  degenerated  into  adeno-
carcinoma),  a  neuroendocrine  tumor  or  a  metastasis  of  a
renal  clear  cell  carcinoma.  The  main  differential  diagnosis
for  serous  cystadenoma,  particularly  in  atypical  presenta-
tions,  however,  is  serous  cyst  adenocarcinoma.  At  present,
there  are  no  histological  criteria  to  differentiate  between
these  two  tumors  and  malignancy  can  only  be  diagnosed
Figure 3. Macroscopic photograph: tumor split open showing
ﬂeshy appearance with a star-shaped ﬁbrous scar (black arrow).

























rom  tumor  invasion  of  adjacent  tissues  and  particularly
rom  metastases  [8],  mostly  to  lymph  nodes  or  the  liver.
his  is,  however,  a  very  rare  diagnosis  with  only  27  cases
eported  in  the  literature  since  1989  [9].  There  is  still  debate
bout  the  treatment  of  these  lesions,  which  mostly  have
 good  prognosis,  particularly  as  surgery  is  very  prone  to
omplications  and  because  of  co-morbidities.  The  unusual
adiological  presentation  of  our  case  (extrinsic  compres-
ion  of  the  Wirsung  duct)  and  unusual  surgical  features
attachment  to  the  vein  wall),  could  have  suggested  a  more
ggressive  form  than  usual  and  we  have  therefore  organized
linical  and  imaging  monitoring.
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